Loading...
XSHE
002424
Market cap914mUSD
Jul 09, Last price  
4.44CNY
1D
-0.89%
1Q
-12.08%
Jan 2017
-75.51%
IPO
20.85%
Name

Guizhou Bailing Group Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002424 chart
P/E
P/S
2.04
EPS
Div Yield, %
Shrs. gr., 5y
-2.51%
Rev. gr., 5y
-0.41%
Revenues
3.05b
-20.31%
601,489,227727,281,988863,756,4491,138,426,6791,367,582,4471,405,330,3301,574,672,1621,899,087,6182,214,211,0732,591,816,6493,136,843,2312,850,585,2493,087,888,2003,111,649,5473,111,123,8273,540,132,2723,540,132,2724,262,971,4393,825,384,5683,048,628,245
Net income
-104m
L
80,295,567111,666,857158,198,365208,381,046221,752,176269,604,481310,477,909411,374,648482,327,101526,137,365563,238,893282,748,969152,375,362118,482,584118,482,589138,473,917138,473,918-414,511,22033,621,934-104,366,037
CFO
749m
+8,200.07%
00125,307,7330201,903,32219,516,226141,756,275395,833,192413,228,742466,615,47979,884,2490467,413,827231,779,655324,922,220502,152,213125,767,0589,020,627748,718,522
Dividend
May 29, 20200.22 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Operating within China, Guizhou Bailing Group Pharmaceutical Co., Ltd. specializes in the full spectrum of activities for traditional Chinese medicine, from initial research and development to manufacturing and market distribution. The company provides a diverse portfolio of medicinal preparations, available in numerous forms including tablets, capsules, granules, liquid syrups, pills, powdered formulations, tinctures, sprays, and topical ointments. These remedies are formulated to address a wide range of health concerns, such as cardiovascular and cerebrovascular conditions, common respiratory issues like coughs and colds, and specific pediatric and gynecological disorders. Established in 2005, its primary operational base is situated in Anshun, China.
IPO date
Jun 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT